NASDAQ$LFST

LifeStance Health Group Inc · Q3 2025 earnings

Q3 2025 earnings · · Before market open · Investor relations

Briefing

LifeStance Health reported Q3 2025, revenue of $363.8M, net income of $1.1M.

LifeStance generated third quarter 2025 revenue of 356800000, representing solid year-over-year growth driven by higher visit volumes and clinician expansion. Net income was 6200000 and Adjusted EBITDA reached 42000000, reflecting continued operating leverage and margin improvement.

  • Revenue increased year-over-year to 356800000 driven by volume growth.
  • Visit volumes grew to 2300000 supported by clinician expansion.
  • Net income improved to 6200000 compared to prior-year loss.
  • Adjusted EBITDA increased to 42000000 reflecting operating leverage.

Headline financials

Total Revenue

$357M

Previous: $313M+14.1%
EPS (adj)

$0.00

Previous: -$0.02+100.0%
Clinicians

8.0K

No prior period
Visit Volumes

2.3M

No prior period
Center Margin

$117M

No prior period
Adjusted EBITDA

$42M

No prior period
Capital Expenditures

-$25.2M

Previous: -$15.3M-65.2%
Net Income

$6.2M

Previous: -$5.96M+204.1%
Operating Income

$9.8M

Previous: $47K+20751.1%

Revenue & EPS history

LifeStance · Revenue · Quarterly

$357M

Q3 2025+14.1%vs Q3 2024
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Forward guidance

The company reaffirmed full year 2025 guidance, expecting continued revenue growth, Center Margin expansion, and Adjusted EBITDA improvement supported by clinician productivity and visit growth.

Tailwinds

  • Sustained double-digit revenue growth.
  • Continued clinician base expansion.
  • Improving operating leverage.
  • Rising Center Margin year-over-year.
  • Strong Adjusted EBITDA growth trajectory.

Headwinds

  • Exposure to reimbursement rate pressures.
  • Dependence on clinician recruitment and retention.
  • Ongoing interest expense impact.
  • Regulatory and healthcare compliance risks.
  • Macroeconomic factors could affect patient demand.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

-4.5%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+1.2%

Avg return

30 days after

42%

8 / 19 earnings

Positive

+24.6%

Q4 2023

Best reaction

-49.7%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+19.8%+7.7%+0.5%
Q4 2025+4.3%+0.0%-11.5%
Q3 2025-3.6%+29.1%+30.1%
Q1 2025-16.0%-10.7%-10.8%
Q4 2024+3.1%+6.8%-10.8%
Q3 2024+3.2%+3.8%+2.9%
Q2 2024+1.6%+6.0%+26.1%
Q1 2024-1.7%+5.9%-19.1%
Q4 2023+24.6%+21.8%-3.4%
Q3 2023-9.4%-8.9%+7.9%
Q2 2023-5.0%-7.4%-17.1%
Q1 2023-1.4%+1.1%+1.7%
Q4 2022+22.2%+23.8%+65.6%
Q3 2022-30.4%-15.9%-23.0%
Q2 2022+6.2%+10.8%+29.3%
Q1 2022-13.9%+0.4%+10.1%
Q4 2021-12.7%-5.9%+4.2%
Q3 2021-27.3%-22.8%-29.1%
Q2 2021-49.7%-40.6%-30.2%
Q1 2021
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro